Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4573925 | 0.98 | CHRM2 (0.38) | CHRM2CHRM1CHRM3HTR2CROCK2 | |
| SCHEMBL7750646 | 0.85 | — | — | |
| SCHEMBL18903009 | 0.85 | — | — | |
| SCHEMBL551606 | 0.78 | CHRNB2 (0.43) | CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL19259428 | 0.76 | CHRNB2 (0.42) | CHRM2CHRM1CHRM3HTR2C | |
| SCHEMBL978739 | 0.76 | MEN1 (0.45) | CHRM2CHRM1CHRM3HTR2CTSHR | |
| SCHEMBL11131656 | 0.75 | HTR2C (0.38) | CHRM2CHRM1CHRM3HTR2CNOS3 | |
| SCHEMBL31370737 | 0.73 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HTR2C | |
| SCHEMBL3645858 | 0.73 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HTR2C | |
| SCHEMBL8600489 | 0.72 | BAZ2A (0.37) | HTR2CNOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963028-B1 | PIPERAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ATIR HOLDING S A (LU) | 2018-08-01 | — | — | EP | disclosed |
| US-9278957-B2 | Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use | ATIR HOLDING S.A. (LU) | 2016-03-08 | — | — | US | disclosed |
| EP-2963028-A1 | PIPERAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Atir Holding S.A. (LU) | 2016-01-06 | — | — | EP | disclosed |
| EP-2435414-B1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ATIR HOLDING S A (LU) | 2015-08-19 | — | — | EP | disclosed |
| US-20150099784-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GROEN AERONAUTICS CORPORATION | 2015-04-09 | — | — | US | disclosed |
| US-8912196-B2 | Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use | ATIR HOLDING S.A. (LU) | 2014-12-16 | — | — | US | disclosed |
| US-20120071487-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ATIR HOLDING S.A. | 2012-03-22 | — | — | US | disclosed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010137018-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ATIR HOLDING S.A. (LU) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1419150-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003101994-A1 | FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003008407-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099784-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | DPYD, BRPF3, BRPF1 | CHRM2 2099/4885CHRM1 2387/4885CHRM3 1993/4885 |
| US-20120071487-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | DPYD, BRPF3, BRPF1 | CHRM2 2099/4885CHRM1 2387/4885CHRM3 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.